The association of ROS1 mutation with cancer immunity and its impact on the efficacy of pan-cancer immunotherapy.

Li, Yingying; Zhao, Hong; Huang, Jinyuan; Yan, Huimeng; Zhao, Bin

Li, Yingying; Zhao, Hong; Huang, Jinyuan; Yan, Huimeng; Zhao, Bin.

Afiliación

Li Y; Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China.
Zhao H; Second Affiliated Hospital, Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
Huang J; The Cancer Center of The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China. doctorhongzhao@163.com.
Yan H; Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China.
Zhao B; Second Affiliated Hospital, Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.

J Transl Med ; 22(1): 403, 2024 Apr 30.

Article en En | MEDLINE | ID: mdl-38689327

Asunto(s)

Inmunoterapia; Mutación; Neoplasias; Proteínas Proto-Oncogénicas; Humanos; Neoplasias/genética; Neoplasias/inmunología; Neoplasias/terapia; Mutación/genética; Proteínas Proto-Oncogénicas/genética; Proteínas Tirosina Quinasas/genética; Inmunidad/genética

Palabras clave

ROS1; Biomarker; Immunotherapy; Tumor immunogenicity; cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas / Inmunoterapia / Mutación / Neoplasias Límite: Humans Idioma: En Revista: J Transl Med Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google